Baird Boosts Price Target on Regeneron (REGN) as Survey Indicates Positive Eylea Momentum
Tweet Send to a Friend
Baird reiterated an Outperform rating Regeneron Pharma (NASDAQ: REGN) and raised its price target to $175.00 (from $150.00).
"We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
"We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
